Serum microRNA-based prediction of responsiveness to eribulin in metastatic breast cancer.

MLA

Satomi-Tsushita, Natsuko, et al. “Serum MicroRNA-Based Prediction of Responsiveness to Eribulin in Metastatic Breast Cancer.” PLoS ONE, vol. 14, no. 9, Sept. 2019, pp. 1–12. EBSCOhost, https://doi.org/10.1371/journal.pone.0222024.

APA

Satomi-Tsushita, N., Shimomura, A., Matsuzaki, J., Yamamoto, Y., Kawauchi, J., Takizawa, S., Aoki, Y., Sakamoto, H., Kato, K., Shimizu, C., Ochiya, T., & Tamura, K. (2019). Serum microRNA-based prediction of responsiveness to eribulin in metastatic breast cancer. PLoS ONE, 14(9), 1–12. https://doi.org/10.1371/journal.pone.0222024

Chicago

Satomi-Tsushita, Natsuko, Akihiko Shimomura, Juntaro Matsuzaki, Yusuke Yamamoto, Junpei Kawauchi, Satoko Takizawa, Yoshiaki Aoki, et al. 2019. “Serum MicroRNA-Based Prediction of Responsiveness to Eribulin in Metastatic Breast Cancer.” PLoS ONE 14 (9): 1–12. doi:10.1371/journal.pone.0222024.